explore -WSS

explore

author：hotspot 2025-09-06 08:25:03 - browse：9684

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

WSS

Gene therapy’s promise and the high cost of hope

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

United colonoscopy coverage change 'may cost lives,' doctors say

Peter Hotez and the public health issue of online harassment

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Wikipedia

explore

explore

Continuity nursing helped my family in our darkest PICU moments

Medicare must police algorithms in Medicare Advantage, Dems say

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Peter Hotez and the public health issue of online harassment

Duchenne breakthrough therapy leaves behind pioneering families

Travis Kelce and the trap of celebrity vaccine endorsements

At least 13 dead in Texas as scorching temps continue

United colonoscopy coverage change 'may cost lives,' doctors say

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

After affirmative action ruling, medical educators look to 'holistic review'

Travis Kelce and the trap of celebrity vaccine endorsements

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Coloradans with cystic fibrosis could lose access to Trikafta

Inari Medical to buy amputation prevention company LimFlow

Wikipedia

hotspot

hotspot

Wikipedia